Abstract

Effect of extended-release quetiapine fumarate on quality of life and sleep in elderly patients with generalized anxiety disorder

Author(s): Catherine Datto, Henrik Svedsater, Julie C Locklear,Jean Endicott

Aims: This prospectively planned analysis evaluates the effects of extendedrelease quetiapine fumarate (quetiapine XR) on quality of life and sleep quality in elderly patients (aged ≥66 years) with generalized anxiety disorder.

Methods: Patients were randomized to quetiapine XR (flexible dosing 50–300 mg/day; n = 223) or placebo (n = 227). The primary end point was least squares mean change from baseline to week 9 in Hamilton Rating Scale for Anxiety total score. Secondary end points were patient-reported outcomes Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q)-Short Form percentage maximum total, Q-LES-Q item 15 (‘satisfaction with medication’), Q-LES-Q item 16 (‘overall life satisfaction’) and Pittsburgh Sleep Quality Index global scores.

Results: At week 9, quetiapine XR significantly improved the Hamilton Rating Scale for Anxiety total score versus placebo (least squares mean change: -14.97 vs -7.21; p < 0.001). Improvement was also observed in Q-LES-Q-Short Form percentage maximum total score, Q-LES-Q item 15 and 16 scores and Pittsburgh Sleep Quality Index global score for quetiapine versus placebo.

Conclusion: In elderly patients with generalized anxiety disorder, quetiapine XR monotherapy (50–300 mg/day flexibly dosed) improved patients’ quality of life, enjoyment, satisfaction and sleep quality.


PDF

Share this       
izmir escort bayan izmir rus escort bursa escort bayan rus escort izmir escort porno indir porno izle mobil porno izmir escort bursa escort türk porno